Tests heart-protecting drugs against chemotherapy heart damage in children
Tests heart-protecting drugs in children with leukemia receiving chemotherapy.
Key facts
- Who runs it
- Ain Shams University
- Where
- Cairo, EgyptSee the site
- Trial code
- Registry title
- Cardioprotection on Chemotherapy-Induced Cardiotoxicity
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 30 people, planned
- Started
- 18 Jul 2023
- Planned end
- 18 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ACE Inhibitors
- β -Blockers
- Record updated
- 3 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with acute leukemia who get chemotherapy. It tests whether heart-protecting medicines guard the heart from chemotherapy damage.
- Age
- 2-18 years at the time of diagnosis (registry minimum age: 1 Year, maximum: 18 Years)
- Sex
- All sexes can join.
Main reasons for not taking part
- Documented allergy to cardioprotective medications
- Cannot take oral medication
- Legal representative does not give informed consent
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Willingness of the legal representative of research participant to participate in the study by giving "informed consent."
- Ability to take oral medication
- Age 2-18 years at the time of diagnosis
Who cannot take part
- Documented allergy to cardioprotective medications
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Where in Egypt
- Faculty of Pharmacy, Ain Shams UniversityCairo, EgyptContact: Aml Elkhouly, Assoc. ProfTaking people
About the trial
What the trial wants to find out
The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.
The 2 groups in the trial
- ACEIsExisting treatment, for comparison
0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.
Treatment: ACE Inhibitors
- β-blockersExisting treatment, for comparison
0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Effect of Cardioprotective Medications on Chemotherapy-Induced Cardiotoxicity in Childhood Acute Leukemia
- Plain-language title
- Tests heart-protecting drugs against chemotherapy heart damage in childrenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06853951, who can take part
- Record updated
- 3 March 2025